NewLink Genetics to Participate in Upcoming Investor Conferences
Aug 29, 2017 11:00 am UTC| Business
AMES, Iowa, Aug. 29, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September: Baird Global Healthcare Conference on September 7 at...
Akcea to Present at Wells Fargo Healthcare Conference
Aug 29, 2017 11:00 am UTC| Business
CAMBRIDGE, Mass., Aug. 29, 2017 -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic...
Ocwen Releases Borrower Assistance Results for First Half of 2017
Aug 29, 2017 10:59 am UTC| Business
Helped 30,000 struggling families avoid foreclosure during the first half of 2017 Reduced consumer mortgage debt by $595 million through borrower assistance programs Distributed over $19.2 million of housing assistance...
USA Parkway Completed Ahead of Schedule; Comstock Secures Valuable Sale of Water Rights
Aug 29, 2017 10:45 am UTC| Business
VIRGINIA CITY, Nev., Aug. 29, 2017 -- Comstock Mining Inc. (“Comstock” or the “Company”) (NYSE American:LODE) announced today that the Nevada Department of Transportation (NDOT) celebrated the completion of the new...
ClubCorp Provides Update on Impact of Hurricane Harvey
Aug 29, 2017 10:45 am UTC| Business
DALLAS, Aug. 29, 2017 -- ClubCorp - The World Leader in Private Clubs® (NYSE:MYCC) - today provided the following update regarding the impact of Hurricane Harvey on its clubs. ClubCorp clubs located in the Houston...
Dougherty’s Pharmacy, Inc. Announces Upgrade to OTCQB® Venture Market
Aug 29, 2017 10:45 am UTC| Business
DALLAS, Aug. 29, 2017 -- Dougherty’s Pharmacy, Inc. (the “Company”) (OTCQB:MYDP) is pleased to announce that it has been approved to upgrade its common stock from the Pink® Open Market to the OTCQB® Venture Market,...
Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors
Aug 29, 2017 10:45 am UTC| Business
Company Announcement Seattle Genetics exercises option to co-develop co-commercialize tisotumab vedotin Costs and profits to be shared 50:50 going forward Lead indication in recurrent cervical cancer;...